Azitra Inc
Azitra Inc (AZTR) is a small, clinical-stage biotechnology company developing microbiome-based treatments for dermatological conditions. Investors should know it is a micro-cap issuer (market capitalisation around $2.05M), which typically implies limited liquidity, higher share-price volatility and greater sensitivity to funding and trial outcomes. The company’s work focuses on harnessing skin microbes and biologics to address inflammatory and infectious skin diseases; programmes are early-stage and outcomes remain uncertain. Financial results, regulatory milestones and clinical data can substantially move the share price in either direction. This summary is educational, not investment advice: potential investors should read the company’s filings, consider the high-risk nature of micro-cap biotech, and assess whether such exposure fits their objectives and risk tolerance. Past performance is not a reliable guide to future returns, and value can fall as well as rise.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Azitra's stock with a target price of $105, indicating strong growth potential.
Financial Health
Azitra Inc has minimal revenue and cash flow, indicating significant financial challenges ahead.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring AZTR
Lottery Tickets
These visionary companies are betting it all on game-changing innovations that could revolutionize entire industries. Hand-selected by our analysts, each represents a high-risk, high-reward opportunity with potential for explosive growth if their breakthrough technologies succeed.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Skin Microbiome Focus
Azitra’s programmes target skin conditions using microbial and biologic approaches — an area of scientific interest, though clinical success is uncertain.
Early-stage Outcomes
Clinical data and regulatory updates can drive sharp moves in the share price; investors should expect high event-driven volatility.
Micro-cap Considerations
With a market cap around $2.05M, liquidity and financing are meaningful risks; suitable only for those comfortable with high-risk investments.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
